EPZM News and Press, Epizyme Inc. From 02/19/20

The FDA Accepts Epizyme Marketing Application Epizyme ( EPZM ) reported that the FDA has accepted its marketing application regarding Tazverik. The treatment is being developed for managing patients with relapsed or refractory lymphoma who have received at least two prior lines of systemi...

Epizyme, Inc . (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2019 financial results and present at upcoming investor conferences. Details o...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 144 weeks of public selections as part of this ongoing live forward-testing. In...

Oncologists may soon have another weapon at their disposal in the fight against advanced follicular lymphoma, a type of cancer in need of new treatment options. The Food and Drug Administration has accepted Epizyme 's (NASDAQ: EPZM) application to review tazemetostat for use by patients with ...

Under Priority Review status, the FDA has accepted Epizyme's (NASDAQ: EPZM ) marketing application seeking approval of Tazverik (tazemetostat) for the treatment of patients with relapsed/refractory follicular lymphoma who have received at least two prior lines of systemic therapy. More n...

Approval Would Expand TAZVERIK™ Label into Second Indication PDUFA Target Action Date Scheduled for June 18, 2020 Epizyme, Inc. (Nasdaq: EPZM), a fully integrated commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U....

Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test now using the top four forensic algorithms applied to detect bankruptcy risk, earnings manipulation, and financial irregularities. This forward testing study co...

Epizyme Wins FDA Approval for Rare Cancer Treatment Tazverik Epizyme (EPZM) received accelerated approval from the Food and Drug Administration for Tazverik (Tazemetostat) treatment for patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma, a rare, slow...

Epizyme (EPZM) announced that it had received accelerated FDA approval of TAZVERIK (tazemetostat) for the treatment of patients with epithelioid sarcoma. This drug, for this specific indication, is estimated to generate roughly $100 million. However, I'm more inclined to say that this approv...

NeuroMetrix (NASDAQ: NURO )  -33%  on Q4 results . More news on: NeuroMetrix, Inc., NIO Limited, Genprex, Inc., Stocks on the move, , Read more ...